Liu Qian, Vice President of AstraZeneca China said on Friday that in Q2 2023, the retail market of chronic disease drugs for hypertension, hyperlipemia, and hyperglycemia, has declined significantly.
Editor:
Alexander
Vice President of AstraZeneca China said the retail market of chronic disease drugs for hypertension, hyperlipemia, and hyperglycemia, has declined significantly
Most Popular
- 1 Meitu partners with Alibaba
- 2 China-Europe Railway Express sees a 9% YoY increase in April
- 3 Tencent Hunyuan unveils Game Visual Generation Platform
- 4 Baidu reportedly plans to launch driverless taxis in Europe
- 5 CATL To Be Included in MSCI Global Standard/ China All Shares Index from 2 Jun
- 6 XPeng Motors reports strong Q1 revenue
- 7 Global data generated set to soar to 393.9 ZB by 2028
川公网安备 51019002001991号
